Formulation development and evaluation of nasal
            <i>in situ</i>
            gel of promethazine hydrochloride

Boraste, Surabhi V.; Patil, Sanjay B.

doi:10.1080/03639045.2023.2291463

Cited by 4 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Poloxamer 407 (X 1 ) and HPMC concentrations (X 2 ) were two independent variables that were optimized for gelation temperature (GT-Y 1 ) and drug release (DR-Y 2 ) as described in a publication before. 31 The optimization was done at five distinct levels and the centre point employing Design-Expert 12 software (Stat Ease Inc., Minneapolis, MN, USA). A total of 13 experimental runs were produced for this investigation employing central composite design (CCD).…”

Section: Optimization Of In Situ Gelmentioning

confidence: 99%

Nasal Administration of Dolutegravir Loaded Nanoparticles Based Mucoadhesive in situ Gel: Design and in vivo Assessment

Sreeharsha,

Cherukuri,

Naveen

et al. 2024

Ind. J. Pharm. Edu. Res

View full text Add to dashboard Cite

Background: To assess the potential for targeting the brain through intranasal delivery, this study focuses on optimizing and developing a mucoadhesive in situ gel formulation containing Dolutegravir nanoparticles. Materials and Methods: Employing a central composite design, the study optimized the concentration of variables of Hydroxypropyl methylcellulose (HPMC, X 1 ) and Poloxamer 407 (X 2 ) on the gelation temperature (Y 1 ) and drug release (Y 2 ). The optimized drug loaded nanoformulations were assessed for various pharmaceutical features, in vitro release and evaluated in vivo. Results: Both variables significantly impacted the responses (p<0.05). The selected formulation displayed beneficial rheological characteristics and prolonged drug release.In vivo pharmacokinetic analysis in rats post-intranasal administration of the optimized in situ gel demonstrated markedly higher (p<0.0001) C max (2-fold) and AUC 0-t (3-fold) values in the targeted brain tissue as compared to intravenous administration. Reduced Dolutegravir exposure in the central compartment validates limited absorption with nasal therapy. Conclusion: The study affirms the potential of the in situ mucoadhesive nasal gel in delivering Dolutegravir to the brain. Thus, the optimized nasal gel emerges as a promising therapeutic alternative for Neuro AIDS by efficiently delivering Dolutegravir to the brain.

show abstract

Section: Optimization Of In Situ Gelmentioning

confidence: 99%